Papers by Christof Wiesner
<p>The mean country estimate for each task is provided in <a href="http://www.ploso... more <p>The mean country estimate for each task is provided in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0157957#pone.0157957.s004" target="_blank">S4 Table</a>. Total active HCP time for IV administration in the UK was 79.5 minutes. HCP, healthcare professional; DPA, drug preparation area; IV, intravenous; SC, subcutaneous.</p
<p>HCP, healthcare professional; DPA, drug preparation area; IV, intravenous; SC, subcutane... more <p>HCP, healthcare professional; DPA, drug preparation area; IV, intravenous; SC, subcutaneous.</p
<p>Study Definitions.</p
<p>Results derived from the random intercept model: infusion time (France, Russia), injecti... more <p>Results derived from the random intercept model: infusion time (France, Russia), injection administration time (France), IV patient chair time (France), SC patient chair time (France). All other results were derived from the standard regression analysis. IV, intravenous; SC, subcutaneous.</p
<p>DPA tasks are in red and treatment room tasks are in blue. *Rituximab syringe can be fil... more <p>DPA tasks are in red and treatment room tasks are in blue. *Rituximab syringe can be filled either in the pharmacy (43%), or in a special aseptic DPA within the day oncology unit (57%). IV, intravenous; SC, subcutaneous; DPA, drug preparation area.</p
<p>Number of Completed Observations by Country.</p
<p>HCP, health care professional; DPA, drug preparation area; IV, intravenous; SC, subcutan... more <p>HCP, health care professional; DPA, drug preparation area; IV, intravenous; SC, subcutaneous.</p
Blood, 2013
Background Rituximab (MabThera®; Rituxan®) is the standard treatment for indolent non-Hodgkin'... more Background Rituximab (MabThera®; Rituxan®) is the standard treatment for indolent non-Hodgkin's lymphoma (iNHL). Results from the phase 3 SABRINA study (NCT01200758) showed that a fixed-dose subcutaneous (SC) formulation of rituximab shortened administration time without compromising efficacy or safety compared with intravenous (IV) infusion of rituximab. A switch to the SC formulation is expected to offer healthcare professionals (HCP) time and cost savings. Aims This study aims to quantify resource utilization in terms of active HCP time (ie, time actively dedicated to a patient) and chair time related to rituximab SC vs rituximab IV in the treatment of patients with iNHL and to estimate potential time and cost savings for the conversion from IV to SC (per administration session and for the first year of treatment). Methods This is a multinational, multicenter, prospective, observational time and motion study. Data for rituximab SC injections were collected alongside the MABCU...
Blood, 2014
BACKGROUND: In Canada, treatment options are limited for patients with chronic lymphocytic leukem... more BACKGROUND: In Canada, treatment options are limited for patients with chronic lymphocytic leukemia (CLL) where fludarabine-based regimens are considered inappropriate. For these patients, chlorambucil monotherapy is considered a standard treatment option. Obinutuzumab is a novel recombinant humanized and glycoengineered Type II anti-CD20 monoclonal antibody of the IgG1 isotype. Clinical data demonstrate that first line therapy with obinutuzumab + chlorambucil can improve progression-free survival (PFS) compared with chlorambucil alone in CLL patients ineligible for fludarabine-based chemotherapy (29.9 vs. 11.1 months; HR 0.18 (95% CI [0.14; 0.24]), p<0.0001). (Goede et al., 2014; Roche. Data on file; May 2014). Obinutuzumab + chlorambucil also demonstrated an overall survival (OS) benefit versus chlorambucil alone (HR for death, 0.47; 95% CI, 0.29 to 0.76; P=0.0014). (Goede et al., 2014; Roche. Data on file; May 2014). We conducted a cost-effectiveness and cost-utility analysis ...
PLOS ONE, 2016
Background Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT0120... more Background Rituximab is a standard treatment for non-Hodgkin lymphoma. The SABRINA trial (NCT01200758) showed that a subcutaneous (SC) rituximab formulation did not compromise efficacy or safety compared with intravenous (IV) infusion. We aimed to quantify active healthcare professional (HCP) time and patient chair time for rituximab SC and IV, including potential time savings. Methods This non-interventional time and motion study was run in eight countries and 30 day oncology units. Rituximab SC data were collected alongside the MabCute trial (NCT01461928); IV data were collected per routine real-world practice. Trained observers recorded active HCP time for pre-specified tasks (stopwatch) and chair time (time of day). A random intercept model was used to analyze active HCP time (by task and for all tasks combined) in the treatment room and drug preparation area, drug administration duration, chair time and patient treatment room time by country and/or across countries. Active HCP and chair time were extrapolated to a patient's first year of treatment (11 rituximab sessions). Results Mean active HCP time was 35.0 and 23.7 minutes for IV and SC process, respectively (-32%, p <0.0001). By country, relative reduction in time was 27-58%. Absolute reduction in extrapolated active HCP time (first year of treatment) was 1.1-5.2 hours. Mean chair time was 262.1 minutes for IV, including 180.9 minutes infusion duration, vs. 67.3 minutes for SC, including 8.3 minutes SC injection administration (-74%, p <0.0001). By country,
Leukemia & Lymphoma, 2015
Chronic lymphocytic leukemia (CLL) is a largely incurable disease which affects patients&amp;... more Chronic lymphocytic leukemia (CLL) is a largely incurable disease which affects patients&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;#39; health related quality of life (HRQL). Treatment is often initiated when symptoms affect HRQL, and patients can experience many rounds of treatment throughout their life. Therefore, the economic burden of CLL can be high. Utility or preference weights for health states reflect the value of HRQL of a given health state and range from 1 (full health) to 0 (dead) and below (negative values possible). Nine health states were developed representing different CLL treatment lines or disease stages. One hundred members of the UK general public valued each health state using the time trade-off methodology. Progression-free survival (PFS) without therapy (mean utility = 0.82) was the least burdensome, with relapsed lines of treatment (mean utility = 0.42) representing the greatest burden. The results underline the value in maintaining a state of PFS for as long as possible.
Uploads
Papers by Christof Wiesner